Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 3, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Lecanemab Questions.

Stephen E Nadeau1

  • 1From the Neurology Service and the Brain Rehabilitation Research Center, Malcom Randall VA Medical Center; Department of Neurology, University of Florida College of Medicine, Gainesville, FL.

Neurology
|March 14, 2024
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of chronic non-cancer pain: a framework.

Pain management·2022
Same author

Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2022
Same author

Basal Ganglia and Thalamic Contributions to Language Function: Insights from A Parallel Distributed Processing Perspective.

Neuropsychology review·2021
Same journal

Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

Neurology·2026
Same journal

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same journal

Early Cerebral Edema Subtypes and Functional Outcome in Patients With Cerebral Venous Thrombosis: Insights From the CLOT-VENUS Registry.

Neurology·2026
Same journal

A Probabilistic Approach to Functional Organization Based on Extraoperative Electrocortical Stimulation Mapping.

Neurology·2026
Same journal

Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial.

Neurology·2026
Same journal

The Influence of Recording Duration and Vigilance State on High-Frequency Oscillation Characterization in Epilepsy.

Neurology·2026
See all related articles

Lecanemab modestly slows Alzheimer's disease progression but presents challenges. Further consideration of its clinical value, treatment burden, and potential side effects like cerebral atrophy is crucial for patient discussions.

Area of Science:

  • Neurology
  • Clinical Trials
  • Pharmacology

Background:

  • Lecanemab, an amyloid-targeting monoclonal antibody, has shown efficacy in slowing early Alzheimer's disease progression.
  • Recent trial results led to FDA approval and widespread adoption, necessitating a critical evaluation of its clinical utility.
  • Concerns exist regarding blinding integrity, potential placebo effects from infusion reactions, and the interpretation of amyloid-related imaging abnormalities.

Purpose of the Study:

  • To critically assess the clinical significance and benefit-risk profile of lecanemab treatment for early Alzheimer's disease.
  • To evaluate the magnitude of lecanemab's effect relative to minimal clinically important differences and existing treatments.
  • To consider the long-term implications of treatment burden, time-value discounting, and potential adverse effects like cerebral atrophy.

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Harvest and Primary Culture of Leptomeningeal Lymphatic Endothelial Cells
06:44

Harvest and Primary Culture of Leptomeningeal Lymphatic Endothelial Cells

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Jul 3, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Harvest and Primary Culture of Leptomeningeal Lymphatic Endothelial Cells
06:44

Harvest and Primary Culture of Leptomeningeal Lymphatic Endothelial Cells

Published on: September 8, 2023

Main Methods:

  • Analysis of data from an 18-month randomized controlled trial of lecanemab.
  • Evaluation of clinical outcomes using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and Alzheimer's Disease Assessment Scale-Cognitive 14 (ADAS-Cog14).
  • Consideration of factors such as blinding success, participant-reported outcomes, treatment burden, and adverse events including cerebral atrophy.

Main Results:

  • Lecanemab demonstrated a statistically significant slowing of cognitive and functional decline in early Alzheimer's disease.
  • The observed benefit on CDR-SB was between 18% and 46% of the minimal clinically important difference.
  • Lecanemab's effect on ADAS-Cog14 at 18 months was half that of donepezil at 6 months, and treatment is associated with progressive cerebral atrophy.

Conclusions:

  • While lecanemab offers a modest benefit, its clinical value is debated due to the magnitude of effect and high treatment burden.
  • Potential placebo effects and the risk of cerebral atrophy warrant careful consideration in patient-physician discussions.
  • Re-evaluation of clinical trial outcome measures and translation into clinical practice is recommended to ensure patient-centered decision-making.